SMN2 and fatty liver disease: Our findings reveal that our novel liver-specific SMN depleted (herein referred to as AlbCre/+;Smn2B/F7) mouse model induces mild liver steatosis and disrupts pancreatic function at postnatal day 19 (P19), characterized by decreased insulin-positive and increased glucagon-positive cells, alongside reduced blood glucose levels.